KAD 1229

Known as: KAD-1229 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1994-2016
024619942016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2004
Review
2004
  • Drugs in R&D
  • 2004
Mitiglinide [KAD 1229, S 21403], a derivative of benzylsuccinic acid, is a potassium channel antagonist undergoing development… (More)
Is this relevant?
2002
2002
1. The effects of KAD-1229 (a novel non-sulphonylurea agent), voglibose (an alpha-glucosidase inhibitor) and nateglinide (a non… (More)
Is this relevant?
2002
2002
The insulinotropic effect of (+)-monocalcium bis [(2S)-2-benzyl-3-(cis-hexahydro-2-isoindolinyl-carbonyl)propionate] dihydrate… (More)
Is this relevant?
2001
2001
Mitiglinide (KAD-1229), a new anti-diabetic drug, is thought to stimulate insulin secretion by closing the ATP-sensitive K+ (K… (More)
Is this relevant?
2001
2001
Hypoglycemic agents with a rapid onset and short duration of action should be useful for controlling postprandial hyperglycemia… (More)
Is this relevant?
1999
1999
1. Hypoglycaemia-inducing sulphonylureas, such as glibenclamide, inhibit cystic fibrosis transmembrane conductance regulator… (More)
Is this relevant?
1996
1996
1. We examined the cooperative effect of a newly synthesized oral hypoglycaemic agent, KAD-1229 with glucose on insulin, glucagon… (More)
Is this relevant?
1996
1996
We investigated therapeutic effects of a rapid- and short-acting non-sulfonylurea hypoglycemic agent, calcium (2S)-2-benzyl-3… (More)
Is this relevant?
1994
1994
Calcium(2s)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl) propionate dihydrate (KAD-1229) was found to have potent… (More)
Is this relevant?
1994
1994
We studied the mechanism of action of KAD-1229, a non-sulfonylurea compound shown to stimulate insulin secretion, in a glucose… (More)
Is this relevant?